Syndax Pharmaceuticals Inc (SNDX) FY2025 10-K Annual Report
Syndax Pharmaceuticals Inc (SNDX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Syndax Pharmaceuticals Inc FY2025 10-K Analysis
Business Overview
- • Commercial-stage biopharma focused on innovative cancer therapies with two FDA-approved drugs: Revuforj (menin inhibitor) and Niktimvo (CSF-1R antibody)
- • New FDA approval in Oct 2025 for Revuforj in relapsed/refractory AML with NPM1 mutation, expanding use beyond KMT2A translocation leukemia
- • Strategic emphasis on frontline combination trials for Revuforj to support label expansion and NCCN guideline inclusion for broader leukemia treatment
- • Launched Revuforj and Niktimvo in US in late 2024/early 2025; Revuforj Phase 3 EVOLVE-2 and REVEAL-ND pivotal trials initiated in 2025 targeting newly diagnosed AML
- • Initiated first clinical data program in 2026 for Revuforj in myelofibrosis and advancing axatilimab in idiopathic pulmonary fibrosis, representing novel disease areas
Management Discussion & Analysis
- • Revenue $172.4M in 2025 vs $23.7M in 2024; net product revenue Revuforj $124.8M vs $7.7M, collaboration revenue Niktimvo $42.4M vs $0
- • Net loss $285.4M in 2025 vs $318.8M in 2024; operating loss $273.1M vs $339.7M; operating margin approx. -158.5% vs -143.3% (losss as % of revenue)
- • Best performing segment: Revuforj product revenue $124.8M; worst: milestone/license revenue down $10.9M to $5.1M
- • Cash, equivalents & short-term investments $394.1M as of Dec 31, 2025; no explicit buybacks/dividends; increased SG&A by $58.8M primarily for commercial launch expenses
- • Forward outlook risk: high interest rates and recession risk may affect financing, inflation could raise operating costs, ongoing clinical and regulatory uncertainties
Risk Factors
- • Cybersecurity risk from IT system compromise with potential regulatory investigations and fines
- • Board audit committee oversees cybersecurity risk management with annual CFO reports on threats and mitigation
- • VP of IT with 25+ years experience responsible for cybersecurity strategy and budget approval
- • Escalation process includes CFO, CEO, and General Counsel for cybersecurity incident response
- • No specific regulatory, geopolitical, supply chain, competitive, or financial risks detailed in text
Syndax Pharmaceuticals Inc FY2025 Key Financial MetricsXBRL
Revenue
$172M
▲ +627.8% YoY
Net Income
-$285M
▲ +10.5% YoY
Operating Margin
-158.4%
▲ +127598bp YoY
Net Margin
-165.6%
▲ +118050bp YoY
ROE
-441.6%
▼ -33099bp YoY
Total Assets
$530M
▼ -26.9% YoY
EPS (Diluted)
$-3.29
▲ +11.6% YoY
Operating Cash Flow
-$323M
▼ -17.5% YoY
Source: XBRL data from Syndax Pharmaceuticals Inc FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Syndax Pharmaceuticals Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.